These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11010647)

  • 1. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
    Fed Regist; 2000 Mar; 65(50):13678-9. PubMed ID: 11010647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
    Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
    Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Aug; 65(167):52016-8. PubMed ID: 11067735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amendment of various device regulations to reflect current American Society for Testing and Material citations. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Jan; 65(15):3584-5. PubMed ID: 11010654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revision of the requirements for live vaccine processing. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):59000-3. PubMed ID: 17966559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amendment to examination and investigation sample requirements--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(186):51297-9. PubMed ID: 10185810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
    Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological technical amendment--FDA. Final rule; technical amendment.
    Fed Regist; 1992 Apr; 57(64):11263. PubMed ID: 10118456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.